Innovating Works

H2020

Cerrada
HORIZON-HLTH-2023-DISEASE...
HORIZON-HLTH-2023-DISEASE-03-17: Pandemic preparedness and response: Understanding vaccine induced-immunity
ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to all of the following expected outcomes:
Sólo fondo perdido 0 €
Europeo
Esta convocatoria está cerrada Esta línea ya está cerrada por lo que no puedes aplicar. Cerró el pasado día 13-04-2023.
Se espera una próxima convocatoria para esta ayuda, aún no está clara la fecha exacta de inicio de convocatoria.
Por suerte, hemos conseguido la lista de proyectos financiados!
Presentación: Consorcio Consorcio: Esta ayuda está diseñada para aplicar a ella en formato consorcio..
Esta ayuda financia Proyectos:

ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to all of the following expected outcomes:

The scientific and clinical communities have an increased knowledge of vaccine-induced immunity and, in particular, a better understanding of factors that affect the magnitude, breadth, nature and duration of immunity to vaccine antigens.The scientific and clinical communities have an increased knowledge of the durability and breadth of vaccine-induced immunity in vulnerable populations and older age groups.The scientific and clinical communities have an increased knowledge of correlates of protection for pathogens with epidemic potential to allow the development of effective vaccines.The scientific and clinical communities have an increased knowledge of the characteristics that influence vaccine effectiveness to allow for novel approaches for the development of vaccines for emerging and re-emerging infections, in... ver más

ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to all of the following expected outcomes:

The scientific and clinical communities have an increased knowledge of vaccine-induced immunity and, in particular, a better understanding of factors that affect the magnitude, breadth, nature and duration of immunity to vaccine antigens.The scientific and clinical communities have an increased knowledge of the durability and breadth of vaccine-induced immunity in vulnerable populations and older age groups.The scientific and clinical communities have an increased knowledge of correlates of protection for pathogens with epidemic potential to allow the development of effective vaccines.The scientific and clinical communities have an increased knowledge of the characteristics that influence vaccine effectiveness to allow for novel approaches for the development of vaccines for emerging and re-emerging infections, including antigenic variants, in the context of epidemic and pandemic preparedness.
Scope:As shown by the COVID-19 pandemic, vaccines are a critical component needed to bring infectious disease pandemics under control. The availability of effective vaccines that are able to induce a strong and durable immune response are critical to respond to health threats caused by infectious disease epidemics or pandemics. A proactive approach to understanding the factors that affect vaccine durability and strength is necessary to ensure development of effective vaccines for future infectious disease outbreaks.

Proposals should study vaccine-induced immunity in the general population and vulnerable groups. Proposals should look both at the magnitude and breadth of initial immune responses and the duration of immunity after vaccination with different vaccine types (mRNA, vector, inactivated, subunit, attenuated,…). Proposals should assess how sex (e.g. male vs female, pre- vs postmenopausal), age (childhood vs adolescent vs elderly) and/or lifestyle (e.g. obesity, drug addiction, diet, sport) affect the immune response. Proposals may also examine genetic and other molecular factors that may influence immune response in humans. Proposals should pursue a multi-omics approach in order to foster a deep understanding of vaccine induced immunity.

Proposals should identify correlates of protection that can be used to develop vaccines against viruses meeting the criteria for pathogens with high pandemic potential as identified by HERA[1].

Proposals should also assess how pre-existing conditions or chronic infections influence the immune response.

Proposals should aim to improve the global vaccine research and development pipeline for emerging and re-emerging viral infections, and to strengthen the current leading role of the EU in vaccine development, and therefore contributing to the work of the European Health Emergency Preparedness and Response Authority (HERA).

This topic requires the effective contribution of social sciences and humanities (SSH) disciplines and the involvement of SSH experts, institutions as well as the inclusion of relevant SSH expertise, in order to produce meaningful and significant effects enhancing the societal impact of the related research activities.

Applicants envisaging to include clinical studies should provide details of their clinical studies in the dedicated annex using the template provided in the submission system. See definition of clinical studies in the introduction to this work programme part.


[1]https://health.ec.europa.eu/system/files/2022-07/hera_factsheet_health-threat_mcm.pdf

ver menos

Temáticas Obligatorias del proyecto: Temática principal:

Características del consorcio

Ámbito Europeo : La ayuda es de ámbito europeo, puede aplicar a esta linea cualquier empresa que forme parte de la Comunidad Europea.
Tipo y tamaño de organizaciones: El diseño de consorcio necesario para la tramitación de esta ayuda necesita de:

Características del Proyecto

Requisitos de diseño: *Presupuesto para cada participante en el proyecto
Requisitos técnicos: ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to all of the following expected outcomes: ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to all of the following expected outcomes:
¿Quieres ejemplos? Puedes consultar aquí los últimos proyectos conocidos financiados por esta línea, sus tecnologías, sus presupuestos y sus compañías.
Capítulos financiables: Los capítulos de gastos financiables para esta línea son:
Personnel costs.
Subcontracting costs.
Purchase costs.
Other cost categories.
Indirect costs.
Madurez tecnológica: La tramitación de esta ayuda requiere de un nivel tecnológico mínimo en el proyecto de TRL 4:. Es el primer paso para determinar si los componentes individuales funcionarán juntos como un sistema en un entorno de laboratorio. Es un sistema de baja fidelidad para demostrar la funcionalidad básica y se definen las predicciones de rendimiento asociadas en relación con el entorno operativo final. + info.
TRL esperado:

Características de la financiación

Intensidad de la ayuda: Sólo fondo perdido + info
Fondo perdido:
Para el presupuesto subvencionable la intensidad de la ayuda en formato fondo perdido podrá alcanzar como minimo un 100%.
The funding rate for RIA projects is 100 % of the eligible costs for all types of organizations. The funding rate for RIA projects is 100 % of the eligible costs for all types of organizations.
Garantías:
No exige Garantías
No existen condiciones financieras para el beneficiario.

Información adicional de la convocatoria

Efecto incentivador: Esta ayuda no tiene efecto incentivador. + info.
Respuesta Organismo: Se calcula que aproximadamente, la respuesta del organismo una vez tramitada la ayuda es de:
Meses de respuesta:
Muy Competitiva:
No Competitiva Competitiva Muy Competitiva
No conocemos el presupuesto total de la línea pero en los últimos 6 meses la línea ha concecido
Total concedido en los últimos 6 meses.
Minimis: Esta línea de financiación NO considera una “ayuda de minimis”. Puedes consultar la normativa aquí.

Otras ventajas

Sello PYME: Tramitar esta ayuda con éxito permite conseguir el sello de calidad de “sello pyme innovadora”. Que permite ciertas ventajas fiscales.
HORIZON-HLTH-2023-DISEASE-03 Pandemic preparedness and response: Understanding vaccine induced-immunity ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination...
Sin info.
HORIZON-HLTH-2023-DISEASE-07-01 European Partnership on Rare Diseases
Expected Outcome:This topic aims at supporting activities that are enabling or contributing to several expected impacts of destination 3 “Ta...
Cerrada hace 1 año | Próxima convocatoria prevista para el mes de
HORIZON-HLTH-2023-DISEASE-03-05 Pandemic preparedness and response: Sustaining established coordination mechanisms for European adaptive platform trials and/or for cohort networks
en consorcio: ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination...
Cerrada hace 1 año | Próxima convocatoria prevista para el mes de
HORIZON-HLTH-2023-DISEASE-03-06 Towards structuring brain health research in Europe
en consorcio: ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination...
Cerrada hace 1 año | Próxima convocatoria prevista para el mes de
HORIZON-HLTH-2023-DISEASE-03-17 Pandemic preparedness and response: Understanding vaccine induced-immunity
en consorcio: ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination...
Cerrada hace 1 año | Próxima convocatoria prevista para el mes de
HORIZON-HLTH-2023-DISEASE-03-07 Relationship between infections and non-communicable diseases
en consorcio: ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination...
Cerrada hace 1 año | Próxima convocatoria prevista para el mes de
HORIZON-HLTH-2023-DISEASE-03-03 Interventions in city environments to reduce risk of non-communicable disease (Global Alliance for Chronic Diseases - GACD)
en consorcio: ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination...
Cerrada hace 1 año | Próxima convocatoria prevista para el mes de
HORIZON-HLTH-2023-DISEASE-03-04 Pandemic preparedness and response: Broad spectrum anti-viral therapeutics for infectious diseases with epidemic potential
en consorcio: ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination...
Cerrada hace 1 año | Próxima convocatoria prevista para el mes de
HORIZON-HLTH-2023-DISEASE-03-18 Pandemic preparedness and response: Immunogenicity of viral proteins of viruses with epidemic and pandemic potential
en consorcio: ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination...
Cerrada hace 1 año | Próxima convocatoria prevista para el mes de
HORIZON-HLTH-2023-DISEASE-03-01 Novel approaches for palliative and end-of-life care for non-cancer patients
en consorcio: ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination...
Cerrada hace 1 año | Próxima convocatoria prevista para el mes de
HORIZON-HLTH-2023-DISEASE-03-18 Pandemic preparedness and response: Sustaining established coordination mechanisms for European adaptive platform trials and/or for cohort networks
en consorcio: ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination...
Cerrada hace 54 años | Próxima convocatoria prevista para el mes de
HORIZON-HLTH-2023-DISEASE-03-18 Contribution to the Coalition for Epidemics Preparedness Initiative (CEPI) - vaccine development for priority diseases
Cerrada hace 54 años | Próxima convocatoria prevista para el mes de